Quantcast

Pacific Biometrics, Inc. To Exhibit at American College of Rheumatology Annual Scientific Meeting in San Francisco October 24-29, 2008

October 22, 2008

Pacific Biometrics, Inc. (OTCBB: PBME), a leading provider of specialty medical laboratory and biomarker assay development and testing services, today announced that it will exhibit its laboratory and contract research services, along with its biomarker assay capabilities, at the ACR/ARHP Annual Scientific Meeting in San Francisco October 24-29, 2008.

The American College of Rheumatology (ACR) is an organization of and for physicians, health professionals and scientists that advances rheumatology through programs of education, research, advocacy and practice support that foster excellence in the care of people with arthritis and rheumatic and musculoskeletal diseases. The Association of Rheumatology Health Professionals (ARP), a division of ACR, is a professional membership society composed of non-physician healthcare professionals specializing in rheumatology, such as advanced practice nurses, nurses, occupational therapists, physical therapists, psychologists, social workers, epidemiologists, physician assistants, educators and researchers.

The ACR/ARP Annual Scientific Meeting meeting will be held at the Moscone Convention Center in downtown San Francisco. Pacific Biometrics will be exhibiting at Booth #1244.

“Pacific Biometrics is active in promoting the standardization of bone metabolism biomarkers and is involved in technologies for monitoring treatment response in diseases such as rheumatoid arthritis (RA) and osteoarthritis (OA),” noted Ron Helm, Chairman and Chief Executive Officer of the Company. “Drug development in these areas requires a range of specialty tests, including markers of bone and cartilage turnover, and markers of systemic and articular inflammation. Earlier this year, as previously announced, a top multinational pharmaceutical company awarded PBI four contracts related to clinical trials that form part of a global development program for an innovative biological treatment for RA. Our work on these contracts will provide essential laboratory data for a pivotal Phase III program. Our worldwide, best-in-class testing of biomarkers as they relate to the diagnosis and treatment of arthritis and a broader range of inflammatory diseases represents a growing area of expertise for PBI, and we look forward to participating in the ACR/ARP Annual Scientific Meeting later this month. At our booth we will showcase our new menu of biomarker assay development services, which is being spearheaded by our new wholly owned subsidiary, Pacific Biomarkers.”

About Pacific Biometrics, Inc. (PBI)

Established in 1989, PBI provides specialized central laboratory and contract research services to support pharmaceutical and diagnostic manufacturers conducting human clinical trial research. The Company provides expert services in the areas of cardiovascular disease, diabetes, osteoporosis, arthritis, and nutrition. The PBI laboratory is accredited by the College of American Pathologists, New York State, and the Lipid Standardization Program. PBI’s clients include many of the world’s largest pharmaceutical, biotech, and diagnostic companies.

Pacific Biomarkers, Inc., incorporated February 1, 2008 as a wholly owned subsidiary of PBI, focuses specifically on the emerging field of biomarker assay development and testing. Services include validating and performing ligand-binding assays for novel clinical biomarkers, immunogenicity testing, and multiplex testing.

PBI is headquartered in Seattle, Washington, and its common stock trades on the OTC Bulletin Board under the symbol “PBME.” For more information about PBI, visit the company’s web site at www.pacbio.com.

Safe Harbor Statement This press release includes forward-looking statements including, but not limited to, the viability and acceptance of the Company’s products and services in the market. These forward-looking statements are subject to a number of risks and uncertainties. These risks include, but are not limited to, the Company’s ability to bid on and win laboratory services contracts, the success of its marketing and business development efforts, competition in the industry, and its ability to manage growth, as well as the risks and other factors set forth in its periodic filings with the U.S. Securities and Exchange Commission (including the Form 10-KSB for the year ended June 30, 2008).

 For Additional Information, Please Contact:  Ron Helm Chairman and CEO (206) 298-0068 or R. Jerry Falkner CFA RJ Falkner & Company, Inc. Investor Relations Counsel (800) 377-9893 Email Contact

SOURCE: Pacific Biometrics, Inc.




comments powered by Disqus